Athenex Inc

NASDAQ:ATNX   3:59:52 PM EDT
3.77
-0.11 (-2.84%)
4:11:02 PM EDT: $3.89 +0.12 (+3.18%)
Products

Athenex Provides Update From FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar For The Treatment Of Metastatic Breast Cancer

Published: 07/06/2021 11:22 GMT
Athenex Inc (ATNX) - Athenex Provides Update From FDA Type a Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer.
Athenex Inc - Held a Type a Meeting With FDA During Q2 of 2021 to Discuss Deficiencies Raised in Crl Received in February.
Athenex Inc - Evaluating Optimal Design for a New Clinical Study Which It Intends to Present to FDA in Q4 of 2021.